ARTS (minerAlocorticoid Receptor antagonist Tolerability Study) (NCT01345656) was a Phase 2a clinical trial in patients with HFrEF (NYHA class II–III symptoms), normal serum potassium, plus mild/moderate CKD [28]. This evidence concerns the gene NR3C2 and chronic kidney disease.